Combination of an hmg-coa reductase inhibitor and a farnesyl-pyrophosphatase synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins
作者： Carlos Lopez-Otin , Nicolas Levy , Pierre Cau
DOI:
关键词: Ageing 、 HMG-CoA reductase 、 Prenylation 、 Progeria 、 Reductase 、 Pharmacology 、 Restrictive dermopathy 、 Biology 、 Persistence (computer science) 、 Biochemistry 、 ATP synthase
摘要: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and farnesyl-pyrophosphate synthase inhibitor, or one their associated physiologically acceptable salts, in preparation composition, particularly pharmaceutical for treatment human animal, pathological nonpathological situations related accumulation and/or persistence prenylated proteins cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy physiological ageing.
lens.org 参考文章(74)
Esteban Martinez, Montserrat Tuset, Ana Milinkovic, José M Miró, José M Gatell, None, Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy. Antiviral Therapy. ,vol. 9, pp. 649- 663 ,(2004)
Ann M. Winter-Vann, Patrick J. Casey, Post-prenylation-processing enzymes as new targets in oncogenesis Nature Reviews Cancer. ,vol. 5, pp. 405- 412 ,(2005) , 10.1038/NRC1612
David D. Pfizer Global Res. Dev. Thompson, Andrew George Pfizer Global Res. Dev. Lee, Wesley Warren Pfizer Global Res. Dev. Day, Compositions and methods for treating osteoporosis ,(2001)
Nicolas Levy, Patrice Bourgeois, Vincent Bonniol, Pierre Cau, Cosmetic and/or dermatological composition ,(2008)
Andrew Spencer, Cindy Maree Baulch-Brown, Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor ,(2003)
Douglas Lytle Mayers, Ulrich Walter Drees, Scott Mccallister, Treatment of hiv infection through combined administration of tipranavir and capravirine ,(2003)
Carlos Lopez-Otin, Nicolas Levy, Pierre Cau, HMG-CoA reductase and farnesyl-pyrophosphate synthase inhibitors for the treatment of conditions related to prenylated proteins in cells ,(2007)